Literature DB >> 27154046

Conditional Disease-free Survival After Radical Prostatectomy: Recurrence Risk Evolution Over Time.

Guillaume Ploussard1, Alexandre de la Taille2, Morgan Moulin2, Yves Allorys3, Claude Abbou2, Laurent Salomon2.   

Abstract

OBJECTIVE: To assess changes in conditional disease-free survival (DFS) rates after radical prostatectomy (RP) and how the impact of well-known prognostic factors evolves over time.
MATERIALS AND METHODS: There were 2813 patients treated with RP and postoperatively followed with clinical and prostate-specific antigen assessments. Estimation of conditional survival (CS) probabilities used the Kaplan-Meier method. Multivariable Cox regression model was used to calculate proportional hazard ratios for prediction of DFS after stratification by prognostics characteristics.
RESULTS: The 5-year DFS rate was 71.2%. The DFS rate 5 years after RP increased to 77.4% (+8.7%), 82.1% (+15.3%), 88.0% (+23.6%), and 94.0% (+32.0%) for patients surviving without recurrence 1, 2, 3, and 4 years after RP, respectively. This represented a relatively stable survival gain per survived year ranging from 5.6% to 8.7%. The conditional 5-year DFS improves mainly for disease-free surviving patients with adverse pathologic factors. Among patients with pT3b-4 disease, the probability of surviving without recurrence to year 5 increased from 20.7% at the time of presentation to 78.9% for patients surviving 4 years without recurrence (+281%) as compared to +12.5% in pT2 disease. The impact of Gleason score and pT stage on CS estimates remained stable over time. Findings were confirmed upon multivariable analyses.
CONCLUSION: The period elapsed from RP is associated with DFS. The risk of recurrence decreases with increasing survivorship, mainly in patients with adverse pathologic factors. CS can provide relevant information for clinicians and patients giving an update of their risk of subsequent recurrence.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27154046     DOI: 10.1016/j.urology.2016.04.031

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Single-fraction image-guided robotic radiosurgery efficiently controls local prostate cancer recurrence after radical prostatectomy.

Authors:  A Spek; A Graser; G Habl; A Muacevic; C Fuerweger; M Seitz; A Haidenberger
Journal:  BJUI Compass       Date:  2020-08-05

2.  Conditional Survival and Time of Biochemical Recurrence of Localized Prostate Cancer in Japanese Patients Undergoing Laparoscopic Radical Prostatectomies.

Authors:  Masayoshi Kawakami; Masanori Hasegawa; Koichiro Yamada; Keisuke Shigeta; Izumi Hanada; Tatsuya Otaki; Kentaro Nagao; Tatsuya Umemoto; Yuuki Shimizu; Hakushi Kim; Nobuyuki Nakajima; Masahiro Nitta; Kazuya Hanai; Yoshiaki Kawamura; Sunao Shoji; Akira Miyajima
Journal:  Ann Surg Oncol       Date:  2020-07-10       Impact factor: 5.344

3.  Conditional biochemical recurrence-free survival after radical prostatectomy in patients with high-risk prostate cancer.

Authors:  Sung-Woo Park; Dae Sung Hwang; Won Hoon Song; Jong Kil Nam; Hyun Jung Lee; Moon Kee Chung
Journal:  Prostate Int       Date:  2020-08-06

4.  Conditional survival of metastatic clear cell renal cell carcinoma: How prognosis evolves after cytoreductive surgery of primary tumor.

Authors:  Haixiang Shen; Jin Liu; Wei Liu; Jiazhu Sun; Xiangyi Zheng; Lisong Teng; Xiao Wang; Liping Xie
Journal:  Cancer Med       Date:  2021-09-12       Impact factor: 4.452

5.  Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy.

Authors:  Shintaro Narita; Kyoko Nomura; Shingo Hatakeyama; Masahiro Takahashi; Toshihiko Sakurai; Sadafumi Kawamura; Senji Hoshi; Masanori Ishida; Toshiaki Kawaguchi; Shigeto Ishidoya; Jiro Shimoda; Hiromi Sato; Koji Mitsuzuka; Tatsuo Tochigi; Norihiko Tsuchiya; Chikara Ohyama; Yoichi Arai; Kengo Nagashima; Tomonori Habuchi
Journal:  Cancer Med       Date:  2019-09-11       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.